PNI as a Potential Add-On Biomarker to Improve the IMDC Intermediate Prognostic Score

Basit Öğe Kaydı
dc.authoridHacioglu, Bekir/0000-0001-8490-3239
dc.authoridSari, Murat/0000-0003-0596-1559
dc.authoridbayoglu, ibrahim vedat/0000-0002-0481-1084
dc.authoridCicin, Irfan/0000-0002-7584-3868
dc.authoridYasar, Alper/0000-0001-8814-8947
dc.authoridTopal, Alper/0000-0002-9679-9245
dc.authorwosidHacioglu, Bekir/GZH-1824-2022
dc.contributor.authorBayoglu, Ibrahim Vedat
dc.contributor.authorHuseynov, Javid
dc.contributor.authorTopal, Alper
dc.contributor.authorSever, Nadiye
dc.contributor.authorMajidova, Nargiz
dc.contributor.authorCelebi, Abdussamet
dc.contributor.authorYasar, Alper
dc.date.accessioned2024-06-12T11:12:33Z
dc.date.available2024-06-12T11:12:33Z
dc.date.issued2023
dc.departmentTrakya Üniversitesien_US
dc.description.abstractIntroduction: This study aimed to assess the role of the adjusted PNI-IMDC risk scoring system in stratifying the intermediate group of metastatic RCC patients who received TKIS in the first-line setting. Methods: A total of 185 patients were included. The adjusted PNI and IMDC model was used to divide the intermediate group into two groups: intermediate PNI-high and intermediate PNI-low groups. The statistical data were analyzed using Kaplan-Meier and Cox regression analysis. Results: The results showed that the adjusted PNI-IMDC risk score, classic IMDC, and PNI had similar prognostic values. Adjusted PNI-IMDC risk score might be used for a more homogeneous differentiation of the classic intermediate group. On the other hand, multivariate analysis revealed that the presence of nephrectomy, adjusted favorable/intermediate (PNI-high) group, ECOG performance score, and presence of bone metastasis were independent predictors of OS. Conclusions: Pre-treatment PNI, as a valuable and potential add-on biomarker to the adjusted PNI-IMDC classification model, can be helpful for establishing an improved prognostic model for intermediate group mRCC patients treated with first-line TKISs. Further validation studies are needed to clarify these findings.en_US
dc.identifier.doi10.3390/jcm12196420
dc.identifier.issn2077-0383
dc.identifier.issue19en_US
dc.identifier.pmid37835062en_US
dc.identifier.scopus2-s2.0-85173857539en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.3390/jcm12196420
dc.identifier.urihttps://hdl.handle.net/20.500.14551/23198
dc.identifier.volume12en_US
dc.identifier.wosWOS:001083637400001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherMdpien_US
dc.relation.ispartofJournal Of Clinical Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectPNIen_US
dc.subjectIMDC Modelen_US
dc.subjectPrognosisen_US
dc.subjectMetastatic RCCen_US
dc.subjectAdjusted PNI-IMDC Modelen_US
dc.subjectRenal-Cell-Carcinomaen_US
dc.subjectClinical-Practice-Guidelinesen_US
dc.subjectSurvivalen_US
dc.subjectValidationen_US
dc.subjectNephrectomyen_US
dc.subjectNivolumaben_US
dc.subjectDiagnosisen_US
dc.subjectCanceren_US
dc.subjectModelsen_US
dc.titlePNI as a Potential Add-On Biomarker to Improve the IMDC Intermediate Prognostic Scoreen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu